Travere CEO Dube to Step Down; Former Amicus CEO Campbell Named as Replacement

Rare Daily Staff

Travere Therapeutics CEO Eric Dube will step down in December after nearly eight years leading the rare-disease drugmaker. The company has named Bradley Campbell, the former president and CEO of Amicus Therapeutics, as his successor.

Campbell will become president, CEO and a member of Travere’s board of directors starting Dec. 1. Dube will remain CEO until then and serve as an executive adviser through Feb. 15, 2027, to support the transition.

Dube’s departure comes after Travere helped bring forward the first approved treatment for focal segmental glomerulosclerosis, or FSGS, a rare kidney disease that can lead to kidney failure.

In a personal statement posted on LinkedIn, Dube said his experience as a two-time survivor of rare cancer had shaped both his life and his leadership.

“When I was first diagnosed at 30, my doctor told me that I was only the seventh person known to have this cancer and that there were no approved treatments if surgery was unsuccessful,” Dube wrote. “I have never forgotten that moment—or the fear and uncertainty of being told that medicine might not have an answer for me.”

He said those experiences left him “impatient for patients” and reinforced his belief that people living with rare diseases deserve to be heard, supported and offered hope.

Dube, now in his mid-50s, said he has been considering the transition for several years. The decision became more urgent, he said, as he continued to face health challenges and reflected on family losses, including the deaths of his uncle and father at relatively young ages.

Dube said he does not plan to take another operating role after leaving Travere. Instead, he intends to remain involved with patients, families and rare-disease advocates in ways that are still taking shape.

Campbell joins Travere after nearly 20 years at Amicus Therapeutics, where he held leadership positions of increasing responsibility before becoming CEO in 2022.

Amicus, which has been acquired by BioMarin Pharmaceutical, grew during Campbell’s leadership from a company centered on a single product into a global rare-disease business with multiple commercial franchises, according to Travere. Earlier in his career, Campbell held commercial and business-development roles at Genzyme and Bristol-Myers Squibb.

Campbell said Travere is entering an important phase in its development and that he sees an opportunity to build on the company’s momentum in rare disease.

“I have long admired Travere’s commitment to the rare disease community, its strong purpose-driven culture and the extraordinary results Eric and the team have delivered,” Campbell said. “I see an exciting opportunity to build on that momentum, reach more people living with rare disease, and continue creating a meaningful value for all stakeholders.”

Photo: Bradley Campbell, who will take the helm of Travere in December.